(Corsee) Sanders Corazon - 26 Nov 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
Director
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
26 Nov 2025
Net transactions value
-$477,763
Form type
4
Filing time
01 Dec 2025, 16:57:56 UTC
Previous filing
09 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sanders Corazon (Corsee) D. Director C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 01 Dec 2025 0001796536

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC American Depositary Shares Options Exercise $417,772 +2,627 $159.03 2,627 26 Nov 2025 Direct F1
transaction ONC American Depositary Shares Sale $620,185 -1,823 -69% $340.20 804 26 Nov 2025 Direct F1, F2
transaction ONC American Depositary Shares Sale $275,349 -804 -100% $342.47 0 26 Nov 2025 Direct F1, F3
holding ONC Ordinary Shares 57,226 26 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONC Share Option (Right to Buy) Options Exercise $0 -34,151 -100% $0.000000 0 26 Nov 2025 Ordinary Shares 34,151 $12.23 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share represents 13 Ordinary Shares.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4 The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F5 The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.